Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Oncternal Therapeutics Analyst Ratings
Buy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalysts
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Oncternal Therapeutics (ONCT) and Ventyx Biosciences (VTYX)
HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Oncternal Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Oncternal Therapeutics, Maintains $1.3 Price Target
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)
H.C. Wainwright Sticks to Its Hold Rating for Oncternal Therapeutics (ONCT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncternal Therapeutics (ONCT), Cassava Sciences (SAVA) and Enanta Pharmaceuticals (ENTA)
Cantor Fitzgerald Adjusts Price Target on Oncternal Therapeutics to $1.30 From $4, Keeps Overweight Rating
Cantor Fitzgerald Maintains Overweight on Oncternal Therapeutics, Lowers Price Target to $1.3
No Data